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Abstract
Pharmacogenomics is the use of genomic and other "omic" information to individualize drug selection and drug use to avoid adverse drug reactions and to maximize drug efficacy. The science underlying pharmacogenomics has evolved rapidly over the 50 years since it was first suggested that genetics might influence drug response phenotypes. That process has occurred in parallel with advances in DNA sequencing and other molecular technologies, with striking increases in our understanding of the human genome. There are now many validated examples of the clinical utility of pharmacogenomics, and this type of clinical genomic information is increasingly being generated in clinical laboratories, incorporated into electronic health records, and used to "tailor" or individualize drug therapy. This review will survey the origins and development of pharmacogenomics; it will address some of the challenges associated with the clinical implementation of pharmacogenomics; and it will attempt to foresee future advances in this important genomic discipline, one that almost certainly will be among the earliest and most widely adopted aspects of clinical genomics. (EHRs), and that information is rapidly becoming an important component of the "therapeutic encounter." As a result, pharmacogenomics is the aspect of clinical genomics that will almost certainly see the earliest and broadest clinical implementation, with the potential to eventually touch the care of every patient everywhere. In subsequent sections, we will briefly review the origins and development of this important aspect of "rational therapeutics," touch briefly on the science underlying pharmacogenomics, address challenges associated with the clinical implementation of this aspect of genomic science, and, finally, describe a vision for a future in which "pharmacogenomics" will have evolved into "pharmaco-omics" and will be an integral component of every medical drug-related therapeutic decision.
PHARMACOGENOMICS: ORIGINS AND DEVELOPMENT
The concept of "pharmacogenetics" was first put forward by the famed American geneticist Arno Motulsky more than a half century ago 4 at a time when it was already becoming clear that variation in drug response could be due, at least in part, to the effects of genetic inheritance. Subsequently, a steady stream of reports appeared that described the contribution of genetics to variation in drug effect. Those examples most often involved pharmacokinetic (PK) factors, that is, factors that influence the concentration of drug that will ultimately reach the therapeutic target. Of those PK factors, most important was genetic variation in the expression and function of drugmetabolizing enzymes, enzymes that can influence plasma drug concentrations. Included among early pioneers in pharmacogenomic research were Werner Kalow at the University of Toronto with his studies of butyrylcholinesterase genetic variation and prolonged apnea after treatment with the muscle relaxant succinylcholine 5, 6 and David Price Evans at Johns Hopkins University who pursued earlier reports 7 of genetic variation in the N-acetylyation of the antituberculosis drug isoniazid. 8, 9 Subsequently, genetic variation in the thiopurine S-methyltransferase (TPMT) enzyme that was associated with potentially life-threatening myelosuppression after treatment with the antineoplastic and immunosuppressant agents mercaptopurine and azathioprine, substrates for metabolism by TPMT, 10, 11 was reported, as was genetic variation in another drugmetabolizing enzyme, cytochrome (CYP) P450 CYP2D6, 12,13 that was associated with variation in plasma concentrations and the therapeutic effects of various drugs. 14, 15 These early examples were discovered at a time before genes were being cloned and sequenced, and they were most often shown to be genetic on the basis of family studies by using techniques similar in principal to those applied by Mendel in the previous century when he performed his famous breeding studies with peas. However primitive they may appear when viewed from the perspective of the present posteHuman Genome Project world, these early examples have stood the test of time and are now well understood mechanistically. They also served as a powerful stimulus that set the stage for a series of systematic attempts to identify, study, and determine the clinical implications for drug response of genetic variation within whole families of genes encoding drug-metabolizing enzymes, drug transporters, and drug targets. Initially, most of those studies continued to focus on PK genes. One reason for that focus was the fact that the variation in PK genes was often associated with relatively easily measured phenotypes, blood drug and drug metabolite concentrations, phenotypes that were often associated with variation in clinical drug response. It should be emphasized that even these early examples served to illustrate that pharmacogenetic variation could result in serious adverse drug reactions and/or striking variation in drug efficacy. It should also be pointed out that drug metabolism may be required to "metabolically activate" a "prodrug," a process that can also be significantly influenced by genetic variation in the biotransformation of the prodrug. We should also make it clear that metabolism is only one of many processes that can result in individual differences in drug response. For example, several severe adverse drug reactions can be predicted and prevented by knowledge of sequence variation involving human leukocyte antigen genes. 16 During the late 1980s and throughout the 1990s, before the completion of the Human Genome Project, pharmacogenomic research often involved cloning and sequencing of genes encoding proteins that might contribute to variation in drug response phenotypes. Those studies found that much of the genetic variation in drug response that had been reported previously resulted from common sequence variation within or near genes that encoded the enzymes that had originally been studied as phenotypes, that is, "high" or "low" levels of enzyme activity. The fact that pharmacogenomic variation was often due to common genetic polymorphisms will come up again subsequently when we cite evidence that every member of our species carries many potentially clinically actionable pharmacogenomic variants. The studies performed during the decade of the 1990s often focused on isoforms of the CYPs as an extremely important family of drug-metabolizing enzymes, 14, 15 but they also included other so-called phase II or conjugating drug-metabolizing enzymes such as sulfotransferases, 17 ,18 methyltransferases such as TPMT, 19, 20 and UDP-glucuronosyltransferases (UGTs). [21] [22] [23] Although research of that era predominantly focused on gene cloning, gene sequencing, and functional characterization of allozymes encoded by variant gene sequences, it was also during that time that we began to understand molecular mechanisms responsible for the functional effects of common genetic variation in those genes. For example, TPMT, as mentioned previously, catalyzes S-methylation, a reaction that inactivates thiopurine drugs such as azathioprine. The most common TPMT variant allele in European populations, TPMT*3A, with a minor allele frequency of approximately 5% resulting in 1 of every 300 Europeans being homozygous for this variant, is due to 2 nonsynonymous (ns) single nucleotide polymorphisms (SNPs) in the TPMT gene. 24, 25 Those 2 changes in the nucleotide sequence result in the alteration of 2 amino acids in the TPMT protein. The protein encoded by TPMT*3A is translated, but it misfolds and is rapidly degraded, [26] [27] [28] with resultant lack of the enzyme and inability to metabolize thiopurines, leading to a 10-fold "overdose" of these cytotoxic agents when "standard" doses of thiopurines are administered to patients who are homozygous for TPMT*3A. Another example illustrating a different type of mechanism involved genetic variation in the TATA box in the promoter for the UGT1A1 gene that encodes a protein that metabolizes bilirubin as well as drugs such as the antineoplastic agent irinotecan. Most people have 6 "TA" elements in this TATA box, but some subjects have 7 rather than 6, and they display decreased expression of both UGT1A1 messenger RNA and protein, resulting in Gilbert syndrome because of reduced bilirubin metabolism and, when they are exposed to irinotecan, an increased incidence of adverse drug reactions such as diarrhea and myelosuppression. 22, 23 These examples and many others illustrate why, at the beginning of the 21st century, with the completion of the Human Genome Project, the stage had been set to move forward quickly with both pharmacogenomic discovery and pharmacogenomic clinical implementation. In a display of the potential power of public-private collaboration, those efforts were enabled by and greatly stimulated in the United States by National Institutes of Health (NIH) Pharmacogenomics Research Network (PGRN) grants from the National Institute of General Medical Sciences and Electronic Medical Records and Genomics (eMERGE) grants from the National Human Genome Research Institutedpublic funding that not only served to drive discovery by providing access to new and expensive techniques such as genome-wide association study (GWAS) and next-generation sequencing (NGS) but also acted as a strong stimulus for the clinical implementation of pharmacogenomics. This brief overview should make it clear that pharmacogenomics as a discipline progressed in parallel with the maturation of genomic science during the later decades of the 20th century and the opening decades of the 21st century.
The progress that has been made in identifying, characterizing, and determining the clinical utility of pharmacogenomic variants since Motulsky first suggested that genetics might influence drug response is illustrated in striking fashion by the information given in Table 1 , which represents a modified version of the US Food and Drug Administration Pharmacogenomics website 29 that lists drugs for which there are pharmacogenomic biomarkers with established clinical utility. It should be noted that Table 1 does not include drugs that are used primarily in oncology, but that information can also be found on the Food and Drug Administration website. The information given in Table 1 also serves to emphasize that virtually every medical discipline is touched by pharmacogenomics, which immediately raises the question of how we can make this 
PHARMACOGENOMICS: CLINICAL IMPLEMENTATION
The rapid growth of clinically relevant pharmacogenomic knowledge, as illustrated by the 127 drugs listed in Table 1 , drugs used to treat patients in virtually every medical specialty, serves to highlight the challenges associated with pharmacogenomic implementation, one of which is that of making this information available to practitioners in a practical and easily understood fashion. To do that requires, among other important steps, objective, evidence-based guidelines and investment in the infrastructure required to make pharmacogenomic information accessible to physicians in a timely fashion. Physicians and other caregivers write prescriptions for drugs, not genes, so the approach that most institutions have taken is to focus on drug-gene pairs. Fortunately, the development of pharmacogenomics has occurred in parallel with the adoption of EHRsda development required for the storage of ever-expanding genomic data as well as the tools required to instantly deliver that information to prescribers, preferably at the point of care, often while the prescription is being written. Of course, it always remains possible for a physician to order a specific pharmacogenomic test, either genotype-based, that is, a test which queries only specific nucleotides that we currently know are of functional significance; or sequence-based for a gene or genes known to be associated with variation in response to a specific drug or drugs. However, pharmacogenomic testing is moving increasingly to the use of panels of "pharmacogenes" that simultaneously test most of the genes that contribute to variation in response to commonly prescribed drugs for which there is evidence of pharmacogenomic clinical utility. To assist caregivers, many institutions have created automatic computerbased alerts that "fire" whenever a drug is prescribed for which a pharmacogenomic test might provide helpful information. For example, at Mayo Clinic, 17 drug-gene pair alerts currently fire when a prescription is first written for a drug that is included among those 17 drug-gene pairs ( Table 2 ). As at many medical centers, review and approval of the implementation of these alerts is the responsibility of a subcommittee of the Formulary Committee. Decision making with regard to the implementation of an alert depends on evidence-based guidelines that come from sources such as the Clinical Pharmacogenetics Implementation Consortium, 30 a collaboration between the PGRN and the PharmGKB database, or a similar European consortium, such as the Dutch Pharmacogenetics Working Group. It should be emphasized that even though this review has generally focused on North American pharmacogenomic discovery and implementation efforts, these efforts are truly international in scope, as illustrated, for example, by the European Ubiquitous Pharmacogenomics Consortium. 31 Current drug-gene pair alerts are primarily "reactive"; that is, they require that the physiciandon the basis of his or her goals for the patientdorder the genetic test in response to the alert. Although an important first step, reactive alerts represent only one step toward the eventual goal, which would involve having pharmacogenomic data for a specific patient "preemptively" available in the EHR so there will be no delay associated with waiting for a test result so the pharmacogenomic information can be incorporated into the clinical workflow seamlessly.
Some academic medical centers are already experimenting with "preemptive" pharmacogenomic alerts. For example, the PGRN centers, as a group, supported a "deep sequencing" facility that developed an NGS reagent that initially included 84 pharmacogenes that were "captured" and sequenced across exons and splice junctions, thus making it possible to obtain information with regard to both known functionally significant variants and many variants of unknown significance. One of the challenges facing pharmacogenomics will be the development of highthroughput methods that will make it possible to functionally characterize the large number of variants of unknown significance identified when we apply NGS to DNA samples from a large number of patients. For example, if we just select 2 common and intensively studied CYP genesdCYP2C9 and CYP2C19dgenes that encode enzymes that metabolize the anticoagulant agents warfarin and clopidogrel, respectively, we can compare what we currently know about these 2 highly studied genes with what we need to know. To determine what "we know," we went to the Human Cytochrome P450 (CYP) Allele Nomenclature Database at the Karolinska in Stockholm. 32 This canonical database for CYP genes and enzymes listed 165 missense variants for CYP2C9 and 189 for CYP2C19. Of those variants, only 29 CYP2C9 variants had been functionally validated (20 in a laboratory setting) and only 26 for CYP2C19 (7 in a laboratory setting). Meanwhile in 60,000 DNA samples for which exome sequence data had been reported by the Broad Institute, 33 there were 235 missense variants in CYP2C9 and 258 in CYP2C19. These numbers indicate that we need to develop methods to rapidly screen the function of these variant allozymes to determine what they might mean clinically. To place this task in context, a decade ago it would have been possible to justify a multiyear PhD thesis project for only a dozen variants of a single gene. This example represents a microcosm of the task that we face as more and more DNA sequence information becomes available. This coming tidal wave of DNA sequence information also raises the issue of the most efficient and cost-effective way to establish the clinical utility of novel pharmacogenomic information. It is clear that it will not be practical to perform a randomized clinical trial for all these genomic variants, but the most practical way in which to do that remains a subject of continuing debate. The NIH PGRN and eMERGE networks have already begun to perform "pilot" studies designed to set the stage for more widespread clinical use of preemptive pharmacogenomic information. For example, each of the NIH eMERGE grant sites used the original PGRNseq NGS reagent to sequence DNA samples from their biobanks. Mayo Clinic, as one example, used this reagent to sequence 1013 DNA samples from the Mayo Clinic Biobank for local patients who had consented for their DNA to be used for research purposes. Patients participating in that "RIGHT" studyd RIGHT drug at the RIGHT dose at the RIGHT timednow have DNA sequence information in the EHR for the 17 drug-gene pairs for which "reactive alerts" are currently firing at Mayo Clinic, but in their case if an alert fires, it will not merely inform the prescriber that a genetic test is available. 34, 35 For these patients, the alert will instantly tell the caregiver the patient's gene sequence with a clinical interpretation. For example, among those original 1013 subjects, if only 5 "common" pharmacogenes out of the 84 sequenced were included, 99.1% of the subjects had at least 1 actionable variant in at least 1 of those 5 genes, with many subjects having clinically actionable variant sequences in several of the 5 genes. 36 This observation explains why, at the beginning of this overview, we made the statement that "pharmacogenomics is the aspect of clinical genomics that will almost certainly see the earliest and broadest clinical implementation, with the potential to eventually touch the care of every patient everywhere." To follow up on those initial RIGHT study results, Mayo Clinic's Center for Individualized Medicine, in collaboration with the Baylor College of Medicine Human Genome Sequencing Center, is currently moving beyond the original 1013 biobank samples to consent and sequence 10,000 additional Mayo Clinic Biobank participants for a RIGHT 10K study designed to test the hypothesis that having preemptive pharmacogenomic information in the EHR might result in cost-effective health benefits for the patients involved, helping them to avoid adverse drug reactions and obtain maximum efficacy from drug therapy.
Finally, it goes without saying that the implementation of pharmacogenomics across a large academic medical center requires significant effort and significant resources. It is for that reason that we emphasized that the NIH support provided by the PGRN and eMERGE grants acted as a valuable "catalyst" to move this aspect of genomic science to the bedside, but that this process must be in a partnership with hospitals and medical centers, beginning with committed institutional leadership; engagement across multiple medical staffs that include physicians, nurses, allied health personnel, and pharmacists, with significant investments required for the education for all these groups, including patients; as well as infrastructural investment in information technology and the EHR. This may seem ambitious but, as outlined subsequently, we are only at the beginning of this process of discovery and implementation of genomics and other "omics" techniques to enhance drug therapy.
PHARMACOGENOMICS: FUTURE PROSPECTS
In this overview, we have described briefly the origins and development of pharmacogenomics as well as ongoing efforts to bring pharmacogenomics into the clinic and to make it a standard component of routine patient care. It might be useful to point out that the TPMT and CYP2D6 genetic polymorphisms that we are currently "implementing" clinically were discovered more than 35 years ago [10] [11] [12] [13] and that both have been known to have clinical utility for more than a quarter of a century. The association of statin-induced myopathy with an SNP in the SLCO1B1 gene was one of the early success stories of pharmacogenomic GWAS, but that occurred a decade ago. 37 Therefore, the information that we are currently implementing in the clinic has been known for decades, or at least for a decade. Included among the questions that we should be asking ourselves now are what are the scientific challenges that face pharmacogenomics as we increasingly apply NGS and increasingly move genome-wide in our perspective as we attempt to apply genomics to "inform" drug selection and use; what other types of "omics" information might help to better inform the "therapeutic encounter"; how we can merge other "omic" information with genomic data; and what other types of information might help make drug selection and use as "rational" and as highly "individualized" as possible. Finally, we should point out that the processes of biomedical "discovery," "translation," and "implementation" are not separate and distinct activities, but rather they are tightly intertwined and they inform each other, as illustrated graphically in Figure 1 .
In subsequent paragraphs, we will briefly outline challenges and possible future directions as genomic science is applied to drug response. That discussion will be followed by a description of recent efforts to move beyond genomics alone to include data from other "omics" disciplines, that is, transcriptomics, epigenomics, proteomics, and metabolomics, in combination with genomics (Figure 2) , to determine whether that might better inform our attempts to optimize and individualize drug therapy by moving beyond pharmacogenomics to what might be called pharmaco-omics.
As pointed out previously, many of the earliest clinically relevant examples of pharmacogenomics involved genes that encoded drugmetabolizing enzymes, drug transporters, and drug targets, proteins that might logically be expected to influence drug response. Furthermore, there was an emphasis on ns SNPs, nucleotide sequence changes in the portion of the gene that encodes protein, resulting in an altered protein amino acid sequence. However, it is becoming increasingly clear now that a large number of GWAS for drug response have been performed, with both drug efficacy and adverse drug reactions as phenotypes, thatdeven though SNPs within the open reading frame of a gene can have a striking effect on functiondmany of the "top hit" SNPs identified during GWAS are outside the coding portion of the gene. Those SNPs often alter transcription, and as a result, they alter gene expression. That can occur, for example, if the SNP either creates or disrupts a transcription factor binding site, a DNA sequence that the transcription factor "recognizes" and binds to in the promoter of the gene or in so-called "enhancer" elements, DNA sequence motifs that can be located hundreds of thousands of base pairs away from the gene. There are now databases that can be used to predict whether an SNP might create or disrupt a transcription factor binding site, and there is also the GTEx database, 38 which, in a tissuespecific fashion, provides information about whether a specific SNP might be an "expression quantitative trait locus"; that is, whether that SNP is associated with variation in the level of messenger RNA expression. To complicate the situation even further, there is recent evidence that SNPs located hundreds of base pairs away from sites of transcription factor binding can have a profound effect on the binding of the transcription factor and on subsequent gene expression. 33, 39 Because exome sequencing covers only about 1.5% of the genome, in the future we will need to move beyond the portion of the gene that encodes protein if we want to understand the functional implications of genetic polymorphisms. There can be no doubt that we are currently missing a great deal of information that might be important for our understanding of variation in drug response. Therefore, new high-throughput approaches will be needed to help us understand and use that information because we are being inundated by a tidal wave of data on genomic sequence variation. 40 The issue of the extremely large number of ns SNP variants within the coding regions of genes and how we can quickly and accurately predict their functional implications that was mentioned previously is just one example of the fact that we are still only at the beginning of our understanding of the relationship of genomic sequence variation to clinically relevant variation in drug response phenotypes. There is no doubt that we will soon be dealing not with hundreds of potentially functionally significant variants for each gene, but rather with thousands. Even if we develop high-throughput methods to determine which gene sequence or structural variants have functional implications, there is no way that a human being could possibly remember all of them; so sophisticated computerized systems will be a necessity, as will systems to convey this information to the health care team caring for the patient in a form that can be easily and quickly understood and used. If that is true of genomics alone, how will we approach the integration of other "omics" information with genomics information with regard to the transcriptome, the epigenome, the proteome, the metabolome, and the microbiome? The process of joining multiple "omics" datasets to help us make better informed therapeutic decisions presents a significant challenge. However, it is now commonplace to use both exome and RNA-seq data, that is, to join genomics and transcriptomics, for a tumor to gain greater insight into underlyingdpotentially "druggable"dtherapeutic targets. That process is also "pharmacogenomics." Psychiatry represents another clinical discipline in which multiple "omics" have been joined. It is probably fair to say that the application of genomics alone has been somewhat disappointing in psychiatrydperhaps, at least in part, because the phenotypes in psychiatry have not yet been closely related to the underlying biology in the same way that they have been in many other medical specialties. In an attempt to overcome that limitation, there have been recent attempts to "inform" genomic analyses by beginning with metabolomic data, determine which metabolite is most highly associated with the psychiatric phenotype (eg, Hamilton D scores for patients with major depressive disorder), perform a GWAS to identify genes associated with the concentration of the metabolite, and then functionally validate the genes/SNPs that were identified during the GWAS. 41 These examples have begun to show us that in the future, biomarkers for drug response might well be composed of genomic data, transcriptomic data, and metabolomic data; that is, that we will be using "pharmacoomics" to help us individualize and optimize drug therapy (Figure 3 ).
CONCLUSION
Pharmacogenomics is the application of genomic and other "omic" information to help guide, inform, and individualize drug therapy. In the decades since Motulsky first put forward the concept of pharmacogenetics, striking progress has been made and there can no longer be any doubt that drug efficacy and the occurrence of adverse drug reactions can be influenced by genomics or that genomic information can be used to help maximize efficacy and minimize the occurrence of adverse drug reactions. That progress has occurred in parallel with the striking advances that have occurred in human genomics during the past half century. As outlined in previous sections, pharmacogenomics and pharmaco-omics are still young disciplines, but they are already moving into the clinic and are already being used to help physicians and other health care team members to make better and more highly individualized therapeutic decisions. Much remains to be done, and we are only at the beginning of the process of bringing this aspect of genomics to the bedside, but we will end this overview as we began: Pharmacogenomics is the aspect of clinical genomics that will almost certainly see the earliest and broadest clinical implementation, with the potential to eventually touch the care of every patient everywhere.
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